MedPath

A comparative study between the efficacy of oral Cimetidine and low dose of systemic Meglumine Antimoniate (MA) with standard dose of systemic (MA) in the treatment of syrian cutaneous leishmaniasis patients.

Phase 3
Conditions
Cutaneous Leishmaniasis.
Cutaneous leishmaniasis
Registration Number
IRCT2013123116016N1
Lead Sponsor
The University of Aleppo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
90
Inclusion Criteria

parasitological confirmation; age between 5 to 65 years old; normal values of the liver, kidney, and pancreas function tests and EKG before treatment.
Exclusion criteria: contraindication to use (MA); pregnant and lactating women; patients with history of cardiac, renal and hepatic diseases; those under treatment with other drugs during the month prior to commencement of the study.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diameter of lesion. Timepoint: Every two weeks from the beginning of the trial up to six weeks and then at 8 and 12 weeks. Method of measurement: Socal Method.
Secondary Outcome Measures
NameTimeMethod
Healing time for lesion. Timepoint: Every two weeks from the beginning of the trial up to six weeks and then at 8 and 12 weeks. Method of measurement: complete response, partial response and no response.
© Copyright 2025. All Rights Reserved by MedPath